Details of the Drug

General Information of Drug (ID: DMJ0QOW)

Drug Name

Rilpivirine

Synonyms

500287-72-9; TMC278; Edurant; TMC 278; UNII-FI96A8X663; R278474; TMC-278; 4-{[4-({4-[(E)-2-Cyanoethenyl]-2,6-Dimethylphenyl}amino)pyrimidin-2-Yl]amino}benzonitrile; CHEBI:68606; FI96A8X663; R 278474; 4-{[4-({4-[(E)-2-cyanovinyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile; (E)-4-((4-((4-(2-cyanovinyl)-2,6-dimethylphenyl)amino)pyrimidin-2-yl)amino)benzonitrile; (E)-4-(4-(4-(2-cyanovinyl)-2,6-dimethylphenylamino)pyrimidin-2-ylamino)benzonitrile; W-202888; RPV; Mu O-conotoxin

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1]
Pain	MG30-MG3Z	Investigative	[2]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

366.4

Topological Polar Surface Area (xlogp)

4.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2235 +/- 851 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 247 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3-4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Clearance: The total clearance of drug is 6.89-8.66 L/h [3]
Elimination: Rilpivirine is 85% eliminated in the feces and 6.1% eliminated in the urine [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 34 - 55 hours [6]
Metabolism: The drug is metabolized via the CYP3A4 and CYP3A5 to the hydroxylated metabolites [7]
Vd: The volume of distribution (Vd) of drug is 152-173 L [3]

Chemical Identifiers

Formula: C22H18N6
IUPAC Name: 4-[[4-[4-[(E)-2-cyanoethenyl]-2,6-dimethylanilino]pyrimidin-2-yl]amino]benzonitrile
Canonical SMILES: CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)/C=C/C#N
InChI: InChI=1S/C22H18N6/c1-15-12-18(4-3-10-23)13-16(2)21(15)27-20-9-11-25-22(28-20)26-19-7-5-17(14-24)6-8-19/h3-9,11-13H,1-2H3,(H2,25,26,27,28)/b4-3+
InChIKey: YIBOMRUWOWDFLG-ONEGZZNKSA-N

Cross-matching ID

PubChem CID: 6451164
ChEBI ID: CHEBI:68606
CAS Number: 500287-72-9
DrugBank ID: DB08864
TTD ID: D0T6WN
INTEDE ID: DR1424
ACDINA ID: D00594

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Inhibitor	[8]
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	TT90XZ8	SCNAA_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]
UDP-glucuronosyltransferase 1A4 (UGT1A4)	DELOY3P	UD14_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Human immunodeficiency virus infection

ICD Disease Classification

1C62

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Voltage-gated sodium channel alpha Nav1.8 (SCN10A)	DTT	SCN10A	9.89E-01	-0.16	-0.31
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	3.80E-01	-9.11E-03	-3.47E-02
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	1.65E-02	-4.37E-02	-7.84E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.90E-01	2.35E-02	7.88E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rilpivirine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[59]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Rilpivirine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[60]
-----------

Coadministration of a Drug Treating the Disease Different from Rilpivirine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Rilpivirine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[60]
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Rilpivirine caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[60]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[61]
Arn-509	DMT81LZ	Major	Increased metabolism of Rilpivirine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[62]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Gilteritinib.	Acute myeloid leukaemia [2A60]	[63]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Ivabradine.	Angina pectoris [BA40]	[64]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[65]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Levalbuterol.	Asthma [CA23]	[66]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Rilpivirine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[67]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Eribulin.	Breast cancer [2C60-2C6Y]	[68]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Rilpivirine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[60]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Rilpivirine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[60]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[69]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[70]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[66]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Osilodrostat.	Cushing syndrome [5A70]	[64]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Rilpivirine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[71]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Rilpivirine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[60]
SODIUM CITRATE	DMHPD2Y	Moderate	Decreased absorption of Rilpivirine due to altered gastric pH caused by SODIUM CITRATE.	Discovery agent [N.A.]	[62]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Rilpivirine and Deutetrabenazine.	Dystonic disorder [8A02]	[72]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Rilpivirine caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[60]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Rilpivirine and Cannabidiol.	Epileptic encephalopathy [8A62]	[64]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Rilpivirine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[60]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Rilpivirine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[73]
ABT-450	DMFW860	Major	Decreased metabolism of Rilpivirine caused by ABT-450 mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[62]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Rilpivirine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[74]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Rilpivirine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[68]
Sodium zirconium cyclosilicate	DMCSLZ4	Moderate	Decreased absorption of Rilpivirine due to altered gastric pH caused by Sodium zirconium cyclosilicate.	Hyperkalaemia [5C76]	[64]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Rilpivirine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[60]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Rilpivirine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[60]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Rilpivirine caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[60]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[64]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Increased metabolism of Rilpivirine caused by Glycerol phenylbutyrate mediated induction of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[60]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Crizotinib.	Lung cancer [2C25]	[75]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Rilpivirine caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[60]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Ceritinib.	Lung cancer [2C25]	[68]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Rilpivirine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[76]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Osimertinib.	Lung cancer [2C25]	[77]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Selpercatinib.	Lung cancer [2C25]	[64]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Rilpivirine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[78]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Rilpivirine and Idelalisib.	Mature B-cell leukaemia [2A82]	[79]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Vemurafenib.	Melanoma [2C30]	[68]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and LGX818.	Melanoma [2C30]	[80]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Rilpivirine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[60]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Siponimod.	Multiple sclerosis [8A40]	[60]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Fingolimod.	Multiple sclerosis [8A40]	[68]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Rilpivirine and Ozanimod.	Multiple sclerosis [8A40]	[81]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Rilpivirine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[60]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Entrectinib.	Non-small cell lung cancer [2C25]	[60]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Rucaparib.	Ovarian cancer [2C73]	[68]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Triclabendazole.	Parasitic worm infestation [1F90]	[68]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Rilpivirine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[82]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[83]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Lefamulin.	Pneumonia [CA40]	[84]
Enzalutamide	DMGL19D	Major	Increased metabolism of Rilpivirine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[62]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Relugolix.	Prostate cancer [2C82]	[64]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Rilpivirine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[60]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Rilpivirine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[64]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Rilpivirine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[60]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[68]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Rilpivirine and Pitolisant.	Somnolence [MG42]	[64]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Rilpivirine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[85]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Rilpivirine and Cabozantinib.	Thyroid cancer [2D10]	[64]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Rilpivirine caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[60]
-----------


⏷ Show the Full List of 64 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 20	E00664	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Rilpivirine 25 mg tablet	25 mg	Oral Tablet	Oral
Rilpivirine Hydrochloride eq 25mg base tablet	eq 25mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
2	Structures of muO-conotoxins from Conus marmoreus. I nhibitors of tetrodotoxin (TTX)-sensitive and TTX-resistant sodium channels in mammalian senso... J Biol Chem. 2004 Jun 11;279(24):25774-82.
3	Australian Government: Australian Public Assessment Report for Rilpivirine
4	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
5	FDA Approved Drug Products: Edurant (rilpivirine) oral tablets
6	Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl). 2011;3:35-44. doi: 10.2147/HIV.S14559. Epub 2011 Apr 28.
7	Duffey H, Firszt R: Management of acute attacks of hereditary angioedema: role of ecallantide. J Blood Med. 2015 Apr 16;6:115-23. doi: 10.2147/JBM.S66825. eCollection 2015.
8	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
9	Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents. 2013 May;41(5):484-7.
10	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
11	Population pharmacokinetics and pharmacogenetics analysis of rilpivirine in HIV-1-infected individuals. Antimicrob Agents Chemother. 2016 Dec 27;61(1).
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
22	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
23	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
24	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
25	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
26	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
27	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
28	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
29	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
30	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
31	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
32	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
33	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
34	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
35	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
36	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
37	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
38	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
39	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
40	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
41	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
42	Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica. 2009 Nov;39(11):826-35.
43	Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol. 2008 Mar 1;75(5):1240-50.
44	Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
45	Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
46	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
47	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
48	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
49	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
50	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
51	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
52	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
53	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
54	Heterologous expression and functional analysis of rat Nav1.8 (SNS) voltage-gated sodium channels in the dorsal root ganglion neuroblastoma cell line ND7-23. Neuropharmacology. 2004 Mar;46(3):425-38.
55	Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. II. Genetic approaches to pain therapy. Am J Physiol Gastrointest Liver Physiol. 2000 Apr;278(4):G507-12.
56	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
57	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
58	Oral Administration of PF-01247324, a Subtype-Selective Nav1.8 Blocker, Reverses Cerebellar Deficits in a Mouse Model of Multiple Sclerosis. PLoS One. 2015; 10(3): e0119067.
59	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
60	Cerner Multum, Inc. "Australian Product Information.".
61	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
62	Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
63	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
64	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
65	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
66	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
67	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68	Canadian Pharmacists Association.
69	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
71	Cerner Multum, Inc. "Canadian Product Information.".
72	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
73	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
74	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
75	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
76	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
78	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
79	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
80	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
81	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
82	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
83	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
84	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
85	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.